Press Release
Enhancing Treatment Efficacy in Multiple Myeloma at ASCO24
Drs. John Sweetenham and Marc Braunstein discuss practice-changing studies in hematologic malignancies that were featured at the 2024 ASCO Annual Meeting, including the ASC4FIRST trial in chronic myeloid leukemia and IMROZ and CARTITUDE-4 in multiple myeloma.
Related Topics
You May Also Like
Article
Median Survival or Mean Survival: Which Measure Is the Most Appropriate for Patients, Physicians, and Policymakers?
Press Release
Announcing the Launch of Voices of Oncology: A Landmark Collaboration with Forbes
Press Release
Introducing OncologyVoiceNetwork.com
Article
Updated estimates of eligibility for and response to genome-targeted oncology drugs among US cancer patients, 2006-2020
Podcast